How Senolytics Work: BCL-2 Family Inhibition and Apoptosis Induction

Expert Summary

Senescent cells are under constant pro-apoptotic pressure from accumulated DNA damage and oncogenic stress. To survive this pressure, they massively upregulate BCL-2 family anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W). Senolytics inhibit these survival proteins, tipping the balance toward apoptosis specifically in cells that depend on them — creating selectivity for senescent over healthy cells.

Key Facts

Frequently Asked Questions

Why don't senolytics kill healthy cells?

Healthy cells are not under high pro-apoptotic pressure (they don't have persistent DNA damage signals driving BAX/BAK activation). BCL-2 inhibition in healthy cells is insufficient to trigger apoptosis. Only cells under intense pro-apoptotic pressure (senescent cells) are vulnerable to BCL-2 family inhibition.

Do cancer cells also express high BCL-2?

Yes — this is why senolytic-like drugs (navitoclax, venetoclax) are used in cancer treatment. BCL-2 family overexpression helps cancer cells resist apoptosis. Senolytic doses in healthy aging individuals are lower than cancer treatment doses, targeting the senescent cell population rather than cancer cells.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.

Scientific References